
Ra Medical Systems RMED
Quarterly report 2025-Q3
added 11-13-2025
Ra Medical Systems Deferred Revenue 2011-2026 | RMED
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Ra Medical Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.8 M | 2.03 M | 1.72 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.03 M | 1.72 M | 1.85 M |
Quarterly Deferred Revenue Ra Medical Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.79 M | 1.78 M | 1.8 M | 1.73 M | 1.86 M | 1.8 M | 2.03 M | 2.03 M | 2.03 M | 2.03 M | 1.72 M | 1.75 M | 1.72 M | 1.72 M | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.03 M | 1.71 M | 1.83 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
14 K | $ 32.5 | -8.14 % | $ 1.44 B | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 13.77 | 4.86 % | $ 1.97 B | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 269.87 | 0.53 % | $ 7.61 B | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.53 | -1.12 % | $ 122 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 14.58 | -1.22 % | $ 394 M | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 6.36 | 0.32 % | $ 457 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 39.87 | 0.77 % | $ 5.94 K | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
313 M | $ 75.27 | 1.21 % | $ 111 B | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 4.52 | - | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
170 K | $ 9.94 | 2.0 % | $ 283 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 14.0 | -1.41 % | $ 905 M | ||
|
Establishment Labs Holdings
ESTA
|
1.75 M | $ 78.78 | 5.1 % | $ 2.22 B | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 99.04 | -2.22 % | $ 1.25 B | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.55 | -0.22 % | $ 122 M | ||
|
Globus Medical
GMED
|
27.7 M | $ 92.25 | -1.25 % | $ 12.5 B | ||
|
LivaNova PLC
LIVN
|
10.8 M | $ 69.26 | 1.32 % | $ 3.76 B | ||
|
Pulmonx Corporation
LUNG
|
135 K | $ 1.51 | 2.03 % | $ 59.1 M | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 1.88 | - | $ 1.14 M | ||
|
Medtronic PLC
MDT
|
315 M | $ 97.06 | -1.57 % | $ 125 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 11.57 | -1.66 % | $ 891 M |